Popular search terms:
Search Results
46 results found-
Safety at CSL
CSL is committed to the development, manufacture and supply of high quality, safe products that save lives and improve the health and wellbeing of patients with serious diseases.
https://corporateresponsibility.csl.com/safety -
Health and Safety
At CSL, we value workplace health, safety and wellbeing for all of our employees. We employ dedicated Employee, Health & Safety (EHS) managers and teams at all our manufacturing sites.
https://corporateresponsibility.csl.com/workplace/health-and-safety -
Plasma Therapies and Vaccines
CSL is committed to the development, manufacture and supply of high quality, safe products that save lives and improve the health and wellbeing of patients with serious diseases.
https://corporateresponsibility.csl.com/safety/plasma-therapies-and-vaccines -
Bioethical Issues
CSL conducts clinical trials in accordance with the current Guideline for Good Clinical Practice (GCP) of the International Conference on Harmonisation (ICH).
https://corporateresponsibility.csl.com/innovation/research-practices/bioethical-issues -
Plasma Donations and Donors
CSL is committed to the development, manufacture and supply of high quality, safe products that save lives and improve the health and wellbeing of patients with serious diseases.
https://corporateresponsibility.csl.com/safety/plasma-donations-and-donors -
Environment
CSL has an Environment, Health, Safety and Sustainability (EHS2) Strategic Plan which ensures its facilities operate to industry and regulatory standards.
https://corporateresponsibility.csl.com/environment -
TM CSL Limited Annual Report 2019/20 Limited CSL Driven by Our Promise by Driven
Maintaining constant communication with patient advocacy groups to provide updates on the continued safety and availability of our plasma-derived products for those living with rare and serious conditions.
https://corporateresponsibility.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2020-full.pdf -
Material Topics
CSL’s Global CR Committee has overall responsibility for the materiality process and executes a global materiality assessment on a biennial basis. In 2017/18, we concluded our third such assessment and followed the Global Reporting Initiative (GRI) standards of sustainability context, materiality, completeness and stakeholder inclusiveness through our process of identification, review and prioritisation. The application and disclosure of our materiality process against the GRI materiality principle definition was externally assured by Ernst & Young.
https://corporateresponsibility.csl.com/approach/material-topics -
Stakeholder Engagement
CSL regards stakeholder engagement as a foundation of corporate responsibility, and have identified our key stakeholders as patient groups, employees, investors, regulators, suppliers, government, healthcare professionals, plasma donors, business partners and the academic and scientific community.
https://corporateresponsibility.csl.com/approach/stakeholder-engagement -
Letter
disclosures inquiring of site personnel to identify risks of underreporting and quality controls to address these risks Employee Health and Safety Total Recordable Injury Frequency Rate (TRIFR) 47 & 150 ► ► undertaking data analytics to check the reasonableness of the data supporting disclosures Talent Recruitment, ► reviewing data and performing recalculations of performance metrics to check reported quantities Employee Opinion Survey 6, 46 & 150 Development and Retention ► on a judgemental sampling basis, requesting and agreeing source evidence to data ► comparing classification of safety incidents against the CSL Standard Operating Procedures to confirm accuracy and Regulatory audits 6, 37 & 150 consistency across the business ► obtaining audit closure reports to confirm existence of quality audits of suppliers and regulatory audits Product Safety and Quality Quality audits of suppliers 34, 37 & 150 ► checking regulatory body websites to confirm accuracy and completeness of safety related recall reporting Safety related recalls of finished product 37 & 150 ► checking aggregation of site-based selected disclosures and transcription to the Report ► evaluating the appropriateness of the presentation relating to the selected disclosures and whether the disclosed Economic value generated 150 information is consistent with our understanding of corporate responsibility management and performance at CSL.
https://corporateresponsibility.csl.com/-/media/corporate-responsibility/documents/csl-cr-assurance-statement-2020.pdf